Close

Leerink Swann Reiterates Outperform on VIVUS (VVUS), Review in Health Economics A Positive

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. HCP
6. SPY
7. BSX
8. PI
9. NOW
10. CNMD


Go back to Leerink Swann Reiterates Outperform on VIVUS (VVUS), Review in Health Economics A Positive

Vivus (VVUS) Financing Agreement Does Not Appear Cheap - Analyst

March 26, 2013 12:56 PM EDT

Wells Fargo today maintained a Market Perform rating on Vivus (NASDAQ: VVUS) with a price target of $12.00. This morning the company announced that it has entered into a $110 million non-equity financing with an investment fund managed by Pharmakon Advisors. Under the terms of this... More

VIVUS (VVUS) Enters $110M non-Equity Financing Agreement; Will Draw $50M Initially

March 26, 2013 6:31 AM EDT

VIVUS, Inc. (Nasdaq: VVUS) announced that it has entered into a $110 million non-equity financing with an investment fund managed by Pharmakon Advisors. Under the terms of this financing, VIVUS will make an initial draw of $50 million and will have the option, at its discretion, to draw an additional $60 million at any... More